tradingkey.logo

Daxor Corp

DXR
12.895USD
+0.515+4.16%
收盤 12/19, 16:00美東報價延遲15分鐘
64.27M總市值
37.08本益比TTM

Daxor Corp

12.895
+0.515+4.16%

關於 Daxor Corp 公司

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Daxor Corp簡介

公司代碼DXR
公司名稱Daxor Corp
上市日期Jul 25, 1983
CEOFeldschuh (Michael Richard)
員工數量- -
證券類型Ordinary Share
年結日Jul 25
公司地址Suite 7120
城市NEW YORK
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編10118
電話12122440555
網址https://www.daxor.com/
公司代碼DXR
上市日期Jul 25, 1983
CEOFeldschuh (Michael Richard)

Daxor Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
212.69K
+1.50%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
35.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
17.05K
+38.62%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
212.69K
+1.50%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
35.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
17.05K
+38.62%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月27日 週四
更新時間: 11月27日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Joseph Feldschuh UEO
51.22%
Feldschuh (Michael Richard)
4.27%
Feldschuh (Jonathan Adam)
1.08%
The Vanguard Group, Inc.
0.98%
Renaissance Technologies LLC
0.58%
其他
41.86%
持股股東
持股股東
佔比
Joseph Feldschuh UEO
51.22%
Feldschuh (Michael Richard)
4.27%
Feldschuh (Jonathan Adam)
1.08%
The Vanguard Group, Inc.
0.98%
Renaissance Technologies LLC
0.58%
其他
41.86%
股東類型
持股股東
佔比
Individual Investor
57.11%
Investment Advisor
1.08%
Hedge Fund
0.58%
Research Firm
0.06%
其他
41.17%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
14
102.17K
2.33%
--
2025Q3
14
102.17K
2.33%
+2.08K
2025Q2
15
100.09K
2.26%
+3.04K
2025Q1
15
97.05K
2.30%
-16.23K
2024Q4
15
106.77K
1.91%
+12.72K
2024Q3
14
94.05K
1.85%
+4.76K
2024Q2
13
89.28K
1.77%
+4.12K
2024Q1
13
85.17K
1.54%
+11.30K
2023Q4
13
73.17K
1.98%
-131.00
2023Q3
12
73.30K
2.02%
-1.71K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Joseph Feldschuh UEO
2.55M
51.22%
--
--
May 19, 2025
Feldschuh (Michael Richard)
212.69K
4.27%
+3.14K
+1.50%
May 19, 2025
Feldschuh (Jonathan Adam)
35.91K
0.72%
--
--
May 19, 2025
The Vanguard Group, Inc.
49.03K
0.98%
--
--
Jun 30, 2025
Renaissance Technologies LLC
28.02K
0.56%
-100.00
-0.36%
Jun 30, 2025
Michel (Robert J)
17.05K
0.34%
+4.75K
+38.62%
May 19, 2025
Morgan Stanley Smith Barney LLC
3.56K
0.07%
+3.47K
+3986.21%
Jun 30, 2025
Desrosiers (Caleb J.D.)
3.16K
0.06%
--
--
May 19, 2025
SBI Securities Co., Ltd.
3.13K
0.06%
--
--
Jun 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Daxor Corp的前五大股東是誰?

Daxor Corp的前五大股東如下:
Joseph Feldschuh UEO
持有股份:2.55M
佔總股份比例:51.22%。
Feldschuh (Michael Richard)
持有股份:212.69K
佔總股份比例:4.27%。
Feldschuh (Jonathan Adam)
持有股份:35.91K
佔總股份比例:0.72%。
The Vanguard Group, Inc.
持有股份:49.03K
佔總股份比例:0.98%。
Renaissance Technologies LLC
持有股份:28.02K
佔總股份比例:0.56%。

Daxor Corp的前三大股東類型是什麼?

Daxor Corp 的前三大股東類型分別是:
Joseph Feldschuh UEO
Feldschuh (Michael Richard)
Feldschuh (Jonathan Adam)

有多少機構持有Daxor Corp(DXR)的股份?

截至2025Q4,共有14家機構持有Daxor Corp的股份,合計持有的股份價值約為102.17K,占公司總股份的2.33% 。與2025Q3相比,機構持股有所增加,增幅為--。

哪個業務部門對Daxor Corp的收入貢獻最大?

在--,--業務部門對Daxor Corp的收入貢獻最大,創收--,占總收入的--% 。
KeyAI